Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness
Space motion sickness (MS) is one of the most important problems in the field of space medicine. In order to prevent space MS, a new medicine, PMPA, has been prepared by means of synthesizing in our laboratory. The purposes of this study were to set up animal models of PMPA against MS, and to observ...
Gespeichert in:
| Veröffentlicht in: | Advances in space research 2002-01, Vol.30 (4), p.751-755 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 755 |
|---|---|
| container_issue | 4 |
| container_start_page | 751 |
| container_title | Advances in space research |
| container_volume | 30 |
| creator | Yang, T.D. Pei, J.S. Yang, S.L. Liu, Z.Q. Sun, R.L. |
| description | Space motion sickness (MS) is one of the most important problems in the field of space medicine. In order to prevent space MS, a new medicine, PMPA, has been prepared by means of synthesizing in our laboratory. The purposes of this study were to set up animal models of PMPA against MS, and to observe its effects on anti-MS, and to prove its function of antagonism to choline. Eight cats, forty rabbits and two hundred and ten rats were selected as animal subjects. The parallel swing stimulus, a method causing the reversal syndromes and tests of anti-choline function were used in our experiments. The results are as follows: (1) The score of MS symptoms in cats with PMPA or scopolamine (SCOP) is significantly lower than that in cats with placebo (p |
| doi_str_mv | 10.1016/S0273-1177(02)00391-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72821231</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0273117702003915</els_id><sourcerecordid>27188480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-ece52e6203da31dd444657fcd04ccb33e75f3d432adaea7604c433ec4e130e173</originalsourceid><addsrcrecordid>eNqFkc1OGzEUha0KVELaRyiaFYLFFF_bEzurCkUtIAWxoF1bjn1HdTt_2DNB7PoQPCFPgieJQOomq6t79N1zpXMI-QL0K1CYXdxTJnkOIOUZZeeU8jnkxQcyASXnOcyFOiCTN-SIHMf4h1JgUtKP5AhYwZSEYkKGW3TemirrAq6x6X3bZG2Zxc5YzOp2s0dv_zYY48u_Z9P4OsF167Aauf43BtPh0HubYVmi7UfVZA0-ZvXo7BvMksV_Tp_IYWmqiJ93c0p-_fj-c3GdL--ubhaXy9wKxvscLRYMZ4xyZzg4J4SYFbK0jgprV5yjLEruBGfGGTRylmSRVCsQOEWQfEpOt75daB8GjL2ufbRYVabBdohaMsWAcdgLMglKCUX3gqDmTEHynJJiC9rQxhiw1F1I2YUnDVSPDepNg3qsR1OmNw3qIt2d7B4Mq5Tg-9WusgR82wKYglt7DDpaj41NaYeUv3at3_PiFeairTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18928112</pqid></control><display><type>article</type><title>Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Yang, T.D. ; Pei, J.S. ; Yang, S.L. ; Liu, Z.Q. ; Sun, R.L.</creator><creatorcontrib>Yang, T.D. ; Pei, J.S. ; Yang, S.L. ; Liu, Z.Q. ; Sun, R.L.</creatorcontrib><description>Space motion sickness (MS) is one of the most important problems in the field of space medicine. In order to prevent space MS, a new medicine, PMPA, has been prepared by means of synthesizing in our laboratory. The purposes of this study were to set up animal models of PMPA against MS, and to observe its effects on anti-MS, and to prove its function of antagonism to choline. Eight cats, forty rabbits and two hundred and ten rats were selected as animal subjects. The parallel swing stimulus, a method causing the reversal syndromes and tests of anti-choline function were used in our experiments. The results are as follows: (1) The score of MS symptoms in cats with PMPA or scopolamine (SCOP) is significantly lower than that in cats with placebo (p<0.01), while the incidences of efficiency and prevention of PMPA (87.5%, 75%) are higher than those of SCOP (75.0%, 50%) in cats. (2) PMPA of 1.6 mg/kg or 0.8 mg/kg could antagonize the reversal syndromes and repress reversal rotation significantly in rabbits like SCOP in comparison with placebo (p<0.01). (3) PMPA could inhibit tremor evoked by oxotremorine or by nicotine-procaine in rats like SCOP, and play an important role in the antagonism to central M-choline and N-choline receptors. The animal experiments demonstrate that PMPA is an effective medicine against MS with antagonism function to choline.</description><identifier>ISSN: 0273-1177</identifier><identifier>EISSN: 1879-1948</identifier><identifier>DOI: 10.1016/S0273-1177(02)00391-5</identifier><identifier>PMID: 12528715</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Acceleration ; Animals ; Antiemetics - therapeutic use ; Cats ; Cholinergic Antagonists - therapeutic use ; Clinical Trials as Topic ; Dose-Response Relationship, Drug ; Drugs, Chinese Herbal - therapeutic use ; Male ; Models, Animal ; Oxotremorine - antagonists & inhibitors ; Rabbits ; Rats ; Scopolamine Hydrobromide - therapeutic use ; Space life sciences ; Space Motion Sickness - drug therapy ; Space Motion Sickness - prevention & control</subject><ispartof>Advances in space research, 2002-01, Vol.30 (4), p.751-755</ispartof><rights>2002</rights><rights>c2002 COSPAR. Published by Elsevier Science Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-ece52e6203da31dd444657fcd04ccb33e75f3d432adaea7604c433ec4e130e173</citedby><cites>FETCH-LOGICAL-c423t-ece52e6203da31dd444657fcd04ccb33e75f3d432adaea7604c433ec4e130e173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0273117702003915$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12528715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, T.D.</creatorcontrib><creatorcontrib>Pei, J.S.</creatorcontrib><creatorcontrib>Yang, S.L.</creatorcontrib><creatorcontrib>Liu, Z.Q.</creatorcontrib><creatorcontrib>Sun, R.L.</creatorcontrib><title>Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness</title><title>Advances in space research</title><addtitle>Adv Space Res</addtitle><description>Space motion sickness (MS) is one of the most important problems in the field of space medicine. In order to prevent space MS, a new medicine, PMPA, has been prepared by means of synthesizing in our laboratory. The purposes of this study were to set up animal models of PMPA against MS, and to observe its effects on anti-MS, and to prove its function of antagonism to choline. Eight cats, forty rabbits and two hundred and ten rats were selected as animal subjects. The parallel swing stimulus, a method causing the reversal syndromes and tests of anti-choline function were used in our experiments. The results are as follows: (1) The score of MS symptoms in cats with PMPA or scopolamine (SCOP) is significantly lower than that in cats with placebo (p<0.01), while the incidences of efficiency and prevention of PMPA (87.5%, 75%) are higher than those of SCOP (75.0%, 50%) in cats. (2) PMPA of 1.6 mg/kg or 0.8 mg/kg could antagonize the reversal syndromes and repress reversal rotation significantly in rabbits like SCOP in comparison with placebo (p<0.01). (3) PMPA could inhibit tremor evoked by oxotremorine or by nicotine-procaine in rats like SCOP, and play an important role in the antagonism to central M-choline and N-choline receptors. The animal experiments demonstrate that PMPA is an effective medicine against MS with antagonism function to choline.</description><subject>Acceleration</subject><subject>Animals</subject><subject>Antiemetics - therapeutic use</subject><subject>Cats</subject><subject>Cholinergic Antagonists - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Male</subject><subject>Models, Animal</subject><subject>Oxotremorine - antagonists & inhibitors</subject><subject>Rabbits</subject><subject>Rats</subject><subject>Scopolamine Hydrobromide - therapeutic use</subject><subject>Space life sciences</subject><subject>Space Motion Sickness - drug therapy</subject><subject>Space Motion Sickness - prevention & control</subject><issn>0273-1177</issn><issn>1879-1948</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1OGzEUha0KVELaRyiaFYLFFF_bEzurCkUtIAWxoF1bjn1HdTt_2DNB7PoQPCFPgieJQOomq6t79N1zpXMI-QL0K1CYXdxTJnkOIOUZZeeU8jnkxQcyASXnOcyFOiCTN-SIHMf4h1JgUtKP5AhYwZSEYkKGW3TemirrAq6x6X3bZG2Zxc5YzOp2s0dv_zYY48u_Z9P4OsF167Aauf43BtPh0HubYVmi7UfVZA0-ZvXo7BvMksV_Tp_IYWmqiJ93c0p-_fj-c3GdL--ubhaXy9wKxvscLRYMZ4xyZzg4J4SYFbK0jgprV5yjLEruBGfGGTRylmSRVCsQOEWQfEpOt75daB8GjL2ufbRYVabBdohaMsWAcdgLMglKCUX3gqDmTEHynJJiC9rQxhiw1F1I2YUnDVSPDepNg3qsR1OmNw3qIt2d7B4Mq5Tg-9WusgR82wKYglt7DDpaj41NaYeUv3at3_PiFeairTw</recordid><startdate>20020101</startdate><enddate>20020101</enddate><creator>Yang, T.D.</creator><creator>Pei, J.S.</creator><creator>Yang, S.L.</creator><creator>Liu, Z.Q.</creator><creator>Sun, R.L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TG</scope><scope>KL.</scope><scope>8FD</scope><scope>H8D</scope><scope>L7M</scope><scope>7X8</scope></search><sort><creationdate>20020101</creationdate><title>Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness</title><author>Yang, T.D. ; Pei, J.S. ; Yang, S.L. ; Liu, Z.Q. ; Sun, R.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-ece52e6203da31dd444657fcd04ccb33e75f3d432adaea7604c433ec4e130e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Acceleration</topic><topic>Animals</topic><topic>Antiemetics - therapeutic use</topic><topic>Cats</topic><topic>Cholinergic Antagonists - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Male</topic><topic>Models, Animal</topic><topic>Oxotremorine - antagonists & inhibitors</topic><topic>Rabbits</topic><topic>Rats</topic><topic>Scopolamine Hydrobromide - therapeutic use</topic><topic>Space life sciences</topic><topic>Space Motion Sickness - drug therapy</topic><topic>Space Motion Sickness - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, T.D.</creatorcontrib><creatorcontrib>Pei, J.S.</creatorcontrib><creatorcontrib>Yang, S.L.</creatorcontrib><creatorcontrib>Liu, Z.Q.</creatorcontrib><creatorcontrib>Sun, R.L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>Technology Research Database</collection><collection>Aerospace Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in space research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, T.D.</au><au>Pei, J.S.</au><au>Yang, S.L.</au><au>Liu, Z.Q.</au><au>Sun, R.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness</atitle><jtitle>Advances in space research</jtitle><addtitle>Adv Space Res</addtitle><date>2002-01-01</date><risdate>2002</risdate><volume>30</volume><issue>4</issue><spage>751</spage><epage>755</epage><pages>751-755</pages><issn>0273-1177</issn><eissn>1879-1948</eissn><abstract>Space motion sickness (MS) is one of the most important problems in the field of space medicine. In order to prevent space MS, a new medicine, PMPA, has been prepared by means of synthesizing in our laboratory. The purposes of this study were to set up animal models of PMPA against MS, and to observe its effects on anti-MS, and to prove its function of antagonism to choline. Eight cats, forty rabbits and two hundred and ten rats were selected as animal subjects. The parallel swing stimulus, a method causing the reversal syndromes and tests of anti-choline function were used in our experiments. The results are as follows: (1) The score of MS symptoms in cats with PMPA or scopolamine (SCOP) is significantly lower than that in cats with placebo (p<0.01), while the incidences of efficiency and prevention of PMPA (87.5%, 75%) are higher than those of SCOP (75.0%, 50%) in cats. (2) PMPA of 1.6 mg/kg or 0.8 mg/kg could antagonize the reversal syndromes and repress reversal rotation significantly in rabbits like SCOP in comparison with placebo (p<0.01). (3) PMPA could inhibit tremor evoked by oxotremorine or by nicotine-procaine in rats like SCOP, and play an important role in the antagonism to central M-choline and N-choline receptors. The animal experiments demonstrate that PMPA is an effective medicine against MS with antagonism function to choline.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12528715</pmid><doi>10.1016/S0273-1177(02)00391-5</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0273-1177 |
| ispartof | Advances in space research, 2002-01, Vol.30 (4), p.751-755 |
| issn | 0273-1177 1879-1948 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72821231 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acceleration Animals Antiemetics - therapeutic use Cats Cholinergic Antagonists - therapeutic use Clinical Trials as Topic Dose-Response Relationship, Drug Drugs, Chinese Herbal - therapeutic use Male Models, Animal Oxotremorine - antagonists & inhibitors Rabbits Rats Scopolamine Hydrobromide - therapeutic use Space life sciences Space Motion Sickness - drug therapy Space Motion Sickness - prevention & control |
| title | Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A34%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medical%20prevention%20of%20space%20motion%20sickness%E2%80%94animal%20model%20of%20therapeutic%20effect%20of%20a%20new%20medicine%20on%20motion%20sickness&rft.jtitle=Advances%20in%20space%20research&rft.au=Yang,%20T.D.&rft.date=2002-01-01&rft.volume=30&rft.issue=4&rft.spage=751&rft.epage=755&rft.pages=751-755&rft.issn=0273-1177&rft.eissn=1879-1948&rft_id=info:doi/10.1016/S0273-1177(02)00391-5&rft_dat=%3Cproquest_cross%3E27188480%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18928112&rft_id=info:pmid/12528715&rft_els_id=S0273117702003915&rfr_iscdi=true |